This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Arvinas‘ lead protein degrader ARV-110 to treat patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after at least two prior therapies, the company announced. Therapies that target the androgen receptor, such…
This post was originally published on this site Women in the European Union with BRCA-mutated advanced ovarian cancer can now receive Lynparza (olaparib) as a first-line maintenance treatment, AstraZeneca and Merck (known as MSD outside the U.S. and Canada) announced. The European Commission’s decision follows a positive recommendation from the Committee for Medicinal Products for Human Use…
This post was originally published on this site CT103A, a fully-human anti-B-cell mature antigen (BCMA) CAR T-cell therapy, leads to strong anti-cancer responses in patients with relapsed or refractory multiple myeloma, including those who relapsed after receiving prior CAR T-cell therapy, data from a trial shows. The findings were presented in a poster, titled “Clinical…
This post was originally published on this site TRQ-1501, an experimental immune cell cancer therapy developed by Torque, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of certain hard-to-treat solid tumors and lymphomas. The designation is given to therapies that show potential to treat serious health conditions,…
This post was originally published on this site A combination of endocrine therapy and the targeted therapy Kisqali (ribociclib) is more effective than endocrine therapy alone at prolonging the survival of premenopausal women who have metastatic hormone receptor-positive breast cancer, a Phase 3 clinical trial suggests. Findings from the MONALEESA-7 trial (NCT02278120) were presented during…
This post was originally published on this site Forty Seven and Acerta Pharma are collaborating to test a triple combination of the investigational 5F9 plus Rituxan (rituximab) and Calquence (acalabrutinib) in patients with diffuse large B-cell lymphoma (DLBCL). The partnership builds on prior Phase 1b data that showed a combination of Forty Seven’s 5F9 and Rituxan was safe and…
This post was originally published on this site A single dose of PolyPEPI1018 — Treos Bio’s investigational off-the-shelf vaccine for colorectal cancer — induced promising immune responses and clinical signs of efficacy when given in combination with standard maintenance therapy in metastatic colorectal cancer patients, interim results from a Phase 1/2 trial show. The findings…
This post was originally published on this site Most prostate cancer patients who choose to undergo active surveillance instead of treatment are not receiving the appropriate disease monitoring, bringing into question whether or not this is a safe treatment option, according to a population-based study. The study, “Population-based cohort of prostate cancer patients on active…
This post was originally published on this site A sentinel node biopsy, used to determine whether cancer has spread to lymph nodes, is a feasible way to obtain information and avoid lymph node dissection in patients with early-stage ovarian cancer, a new study shows. The study, “Sentinel-Node Biopsy in Early Stage Ovarian Cancer: Preliminary Results…
This post was originally published on this site Ygalo (melflufen) combination therapy continues to lead to clinically meaningful responses, without significant side effects, in patients with relapsed or refractory multiple myeloma, updated data from Phase 1/2 trials show. The new findings were presented in two posters, titled “ANCHOR (OP-104): A Phase 1 study update of…
